Stoke Therapeutics (NASDAQ: STOK) said that Chief Patient Officer Jason Hoitt sold a total of 3,712 shares of company common stock over two days, March 17 and March 18, 2026, according to a regulatory filing.
The combined proceeds from the transactions amounted to $119,310. Reported sale prices ranged between $31.28 and $33.38 per share, and the filings indicate the disposition was executed to cover tax withholding liabilities stemming from the vesting and settlement of restricted stock units (RSUs).
Transaction details in the filing show multiple tranches:
- March 17: 1,033 shares sold at a weighted average price of $32.7394, with individual prices in the range of $31.995 to $32.99.
- March 17: an additional 748 shares sold at a weighted average of $33.3754, with prices between $33.00 and $33.855.
- March 18: 1,762 shares sold at a weighted average price of $31.2838, with sale prices ranging from $30.59 to $31.58.
- March 18: 139 shares sold at a weighted average of $31.7888 (range: $31.60 to $32.46).
- March 18: 30 shares sold at $32.85 each.
After these dispositions, Hoitt is reported to directly own 10,276 shares of Stoke Therapeutics. The stock was trading at $33.19 at the time of the reporting, and the filing notes that the sales were made specifically to satisfy withholding obligations tied to RSU vesting and settlement.
Market performance metrics noted alongside the filing show the share price has fallen roughly 9% over the past week while remaining more than 300% higher versus the same point last year.
Separately, Stoke disclosed an executive bonus and received recent analyst attention as it advances its lead program. The company awarded CEO Ian F. Smith a bonus totaling $697,125, citing clinical and financial performance under his leadership; the disclosure also states that Smith did not participate in the 2025 annual bonus program.
On the coverage front, Guggenheim initiated coverage of Stoke with a Buy rating and a $60.00 price target, highlighting the potential of the company's lead therapeutic candidate, zorevunersen, for the treatment of Dravet syndrome. Cantor Fitzgerald has maintained an Overweight rating on the stock and noted ongoing discussions between the company and the U.S. Food and Drug Administration regarding expedited regulatory pathways.
Stoke updated the timeline for its Phase 3 EMPEROR trial of zorevunersen, now projecting completion of patient enrollment in the second quarter of 2026 and anticipating a data readout in mid-2027. The company intends to initiate a rolling New Drug Application (NDA) submission to the FDA in the first half of 2027.
These corporate and clinical updates accompany the insider sale and analyst activity, giving investors more detail on both executive compensation decisions and program milestones as Stoke navigates regulatory engagement and the next stages of its clinical development plan.
Summary of the key facts:
- Insider sales: 3,712 shares sold March 17-18, 2026; proceeds of $119,310; sale prices ranged $31.28 - $33.38.
- Purpose of sale: to cover tax withholding related to RSU vesting and settlement.
- Remaining insider holdings: Hoitt directly owns 10,276 shares following the sales.
- Corporate updates: CEO bonus of $697,125; Guggenheim Buy rating with $60 target; Cantor Fitzgerald Overweight rating; updated EMPEROR timeline with enrollment completion expected in Q2 2026 and data readout in mid-2027; rolling NDA planned for H1 2027.